University Of Antwerp

7 trials 4 recruiting Academic / non-commercial

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

4 Countries active

8 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 1 Phase II: 2 Phase I/II: 1 Phase IV: 3

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Avian influenza 1

Top IMPs

BOTULINUM TOXIN TYPE A 1 BRETOVAMERAN 1 CELECOXIB 1 DIPHTHERIA TOXOID, TETANUS TOXOID, PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, PERTUSSIS PERTACTIN, PERTUSSIS FIMBRIAL AGGLUTINOGENS (FIM) 2 AND 3 1 GALLIUM (68GA), PENTIXAFOR 1 HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA, HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE PARTICLES PRODUCED IN YEAST CELLS (SACCHAROMYCES CEREVISIAE CANADE 3C-5 (STRAIN 1895)) BY RDNA 1 INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8)-LIKE STRAIN (CBER-RG8A) (CLADE 2.3.4.4B) 1 MINOCYCLINE 1

All trials

7 total

The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women (MATI… Pending

2024-518692-56-00 Phase IV 1 country DIPHTHERIA TOXOID, TETANUS TOXOID, PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMA…
Developing a first-void urine-based infection model to assess HPV virion infectivity after vaccination. Recruiting

2025-522053-18-00 Phase II 1 country HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
STROKE-POC Recruiting

2024-510866-18-00 Phase II 2 countries BOTULINUM TOXIN TYPE A
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma Recruiting

2022-501811-14-00 Phase I/II 2 countries GALLIUM (68GA), PENTIXAFOR
INSTA-MD: INflammation-based Stratification for immune-Targeted Augmentation in Major Depressive disorder Recruiting

2022-501692-35-00 Phase III 1 country CELECOXIB; MINOCYCLINE
Phase IV multicenter trial to evaluate the immunogenicity and safety of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults pre… Ended

2025-522116-16-00 Phase IV 2 countries INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8)-LIKE STRAIN (CBER-RG8A) (CLADE 2.3.4.4B)
A phase 4, open-label study to evaluate the short-term innate immune response after administration of a COVID-19 mRNA vaccine (Comirnaty JN… Ended

2024-520304-26-00 Phase IV 1 country BRETOVAMERAN

Showing 1–7 of 7 trials

← All sponsors A–Z